AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20678687
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of glimepiride 2 mg + metformin 500 mg
Trial: 12473010
Drug: Facility characteristics
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facility characteristics (e.g., Medicare recipients, staffing levels, environmental quality)
Trial: 12473010
Drug: Facility characteristics
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facility characteristics (e.g., for-profit ownership, chain affiliation)
Trial: 2298963
Drug: Plasmapheresis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis therapy
Trial: 2298963
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and immunosuppressive drugs alone (Control)
Trial: 80682
Drug: Prednisolone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (60 mg daily for one week, 40 mg daily for four days, and then 30 mg daily for three days)
Trial: 27374276
Drug: Synthetic MK-7
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic MK-7 (180 µg)
Trial: 27374276
Drug: Fermentation-derived MK-7
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermentation-derived MK-7 (90 µg)
Trial: 27374276
Drug: Synthetic MK-7
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic MK-7 (45 µg)
Trial: 27374276
Drug: Synthetic MK-7
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic MK-7 (90 µg)
Trial: 25686683
Drug: 36 months
RxNorm normalized name: influenza virus vaccine qs 2016-17 (36 months up)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 months of isoniazid preventive therapy (36IPT)
Trial: 25686683
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of isoniazid preventive therapy (6IPT)
Trial: 24634622
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement splint (MAS) therapy
Trial: 11391278
Drug: N-duopropenide alcohol
RxNorm normalized name: n-decyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-duopropenide alcohol solution (NDP)
Trial: 9014908
Drug: Plasma Exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Exchange (PE) - five 50 mL/kg exchanges over 8-13 days
Trial: 9014908
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Immunoglobulin (IVIg) - Sandoglobulin, 0.4 g/kg daily for 5 days
Trial: 9014908
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PE followed by IVIg)
Trial: 9014908
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PE + IVIg)
Trial: 25494343
Drug: Post-treatment proposals
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment proposals participation
Trial: 18669426
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 2.5 mg of cyclosporine per kilogram of body weight
Trial: 9485968
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml hyperbaric 0.5% bupivacaine
Trial: 9485968
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml hyperbaric 0.5% bupivacaine
Trial: 2422463
Drug: Nifedipine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (3 doses of 20 mg given sublingually at 8‐h intervals)
Trial: 24627629
Drug: Exercise Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Therapy
Trial: 23292820
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality (VR) supermarket (VMall) treatment, 10 sessions of 45 minutes each.
Trial: 23292820
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (OT) cognitive retraining without VR, 10 sessions.
Trial: 19139601
Drug: Strict treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict treatment to maintain systolic blood pressure below 140 mmHg
Trial: 19139601
Drug: Mild treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg
Trial: 10967067
Drug: L-NMMA (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (6 mg/kg over 5 minutes followed by 60 microg/kg per minute over 55 minutes)
Trial: 10967067
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg over 5 minutes followed by 30 microg/kg per minute over 55 minutes)
Trial: 24569127
Drug: Alfacalcidol (ACD)
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (ACD) at 0.5 μg/day (n = 14)
Trial: 7575103
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at low plasma level (2 ng/mL)
Trial: 7575103
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at moderate plasma level (10 ng/mL)
Trial: 2075079
Drug: Intravenous cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefuroxime 1,500 mg plus 500 mg metronidazole
Trial: 7353344
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (15,000 U)
Trial: 24084509
Drug: Almonds consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds consumed with breakfast (43 g/day)
Trial: 24084509
Drug: Almonds consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds consumed as a morning snack (43 g/day)
Trial: 24084509
Drug: Almonds consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds consumed as an afternoon snack (43 g/day)
Trial: 8996142
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC of 4 (AUC4) and cyclophosphamide 500 mg/m2
Trial: 8996142
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC of 8 (AUC8) and cyclophosphamide 500 mg/m2
Trial: 8512006
Drug: Metoprolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (up to 200 mg/die intravenously)
Trial: 29522113
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate, administered in 3 rounds over a 3-day course.
Trial: 29522113
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate.
Trial: 26576633
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition group (treatment as usual)
Trial: 18512165
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN) patches
Trial: 18512165
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stopping or continuing antihypertensive treatments)
Trial: 15778907
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (lidocaine 5% patch, IBSA)
Trial: 7577287
Drug: Clonidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (5 micrograms kg‐1) with famotidine 20 mg
Trial: 7577287
Drug: Control (famotidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (famotidine 20 mg alone)
Trial: 30967099
Drug: 1.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 mg/kg oral racemic MDA
Trial: 25997508
Drug: Methyl aminolaevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate cream (MAL)
Trial: 25997508
Drug: 5-ALA gel
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA gel (BF-200 ALA)
Trial: 19567246
Drug: Francisella tularensis
RxNorm normalized name: Francisella tularensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(7) cfu/ml
Trial: 19567246
Drug: Francisella tularensis
RxNorm normalized name: Francisella tularensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(9) cfu/ml
Trial: 19567246
Drug: Francisella tularensis
RxNorm normalized name: Francisella tularensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(5) cfu/ml
Trial: 19567246
Drug: Francisella tularensis
RxNorm normalized name: Francisella tularensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SQ at 10(5) cfu/ml
Trial: 16397129
Drug: Tandem autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem autologous stem cell transplantation (ASCT) prepared by melphalan 220 mg/m(2) and 160 mg dexamethasone with or without anti-IL-6 monoclonal antibody (IFM99-04 protocol)
Trial: 16397129
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation followed by dose-reduced allogeneic stem cell transplantation (IFM99-03 trial)
Trial: 15132026
Drug: Walking whilst
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Walking whilst swinging arms at twice the natural frequency
Trial: 9160765
Drug: Isradipine SRO
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine SRO (IS) 5 mg
Trial: 9160765
Drug: Spirapril (SP)
DrugBank: Spirapril (DB01348)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spirapril (SP) 6 mg
Trial: 2965232
Drug: ANP against
RxNorm normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP against a nonpressor background infusion of ANG II
Trial: 2965232
Drug: ANP against
RxNorm normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP against a background infusion of ANG II
Trial: 29799968
Drug: Daily sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sublingual buprenorphine with naloxone (SL-BPN/NX group)
Trial: 29799968
Drug: Weekly and
RxNorm normalized name: Ezy Dose Weekly And Portable Pill Planner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly and monthly subcutaneous buprenorphine (SC-BPN group)
Trial: 16337041
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day (n = 24)
Trial: 10952950
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and nimesulide
Trial: 8793447
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a self-management plan (SM)
Trial: 8793447
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a doctor-managed regimen (DM)
Trial: 1661247
Drug: Psychologically oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychologically oriented treatment for alcoholism during hospitalization (16 +/- 10 days, 1 to 4 psychotherapeutic interviews)
Trial: 1661247
Drug: Psychologically oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychologically oriented treatment for alcoholism
Trial: 571202
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk with 1.75 g/kg of body weight of lactose
Trial: 571202
Drug: Aqueous lactose
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous lactose solution
Trial: 31470168
Drug: High-implant density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-implant density (HID)
Trial: 31470168
Drug: Low-implant density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-implant density (LID)
Trial: 19133704
Drug: Armodafinil (50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (50-400 mg, once daily for up to 14 days)
Trial: 19133704
Drug: Armodafinil (50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (50-400 mg)
Trial: 16024131
Drug: IGF-I therapy
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I therapy (20 microg/kg/day with dose escalation to 50-100 microg/kg/day for 4 months)
Trial: 2792920
Drug: Oral tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tinidazole (150 mg X 2) for 7 days
Trial: 2792920
Drug: Oral tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days
Trial: 2792920
Drug: Intravaginal tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks
Trial: 2792920
Drug: Intravaginal tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks with IUCD
Trial: 2792920
Drug: Oral tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tinidazole (150 mg X 2) for 7 days with IUCD
Trial: 2792920
Drug: Oral tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days and IUCD
Trial: 18476432
Drug: Qianlie Huazhuo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlie Huazhuo Capsule (QHC)
Trial: 18476432
Drug: Qianlie Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlie Jiedu Capsule (Control)
Trial: 10540069
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol and remifentanil (125 microg of remifentanil added to 500 mg of propofol)
Trial: 8712091
Drug: Bicalutamide (10-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (10-100 mg orally daily for 12 weeks)
Trial: 7049311
Drug: Rectal metronidazole
RxNorm normalized name: metronidazole Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal metronidazole twice-daily for 5 days
Trial: 7049311
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further antibacterial treatment
Trial: 31445345
Drug: Escitalopram 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 30 mg per day
Trial: 31445345
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg per day plus placebo
Trial: 29911768
Drug: Single-shot sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot sciatic nerve block (SNB) with 0.25% bupivacaine 25 ml + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Trial: 29911768
Drug: Parenteral parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parenteral parecoxib 40 mg q 12 hours + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Trial: 29911768
Drug: Only continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Trial: 25982007
Drug: Reinforcement-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement-Based Treatment (RBT) plus low cost Contingency Management (CM)
Trial: 25982007
Drug: Reinforcement-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement-Based Treatment (RBT)
Trial: 22464778
Drug: Warming kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming kidney prescription treatment
Trial: 22464778
Drug: Control (telbivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (telbivudine monotherapy only)
Trial: 8338943
Drug: Pentoxifylline (PTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX), 1,600 mg/d in four divided doses from day -8 until day +100 post-BMT
Trial: 3520988
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with azathioprine and high‐dose steroids
Trial: 29284645
Drug: Parenting program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenting program focused on reading aloud; included borrowing children's books weekly and monthly parent workshops.
Trial: 20012230
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell therapy
Trial: 7498223
Drug: Planar thallium-201
RxNorm normalized name: thallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planar thallium-201 perfusion and FDG metabolism imaging
Trial: 2108113
Drug: Aminoglycosides given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides given once daily (4.5 mg/kg bodyweight/day)
Trial: 2108113
Drug: Aminoglycosides given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides given three times a day (4.5 mg/kg bodyweight/day)
Trial: 2108113
Drug: Gentamicin once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin once daily
Trial: 2108113
Drug: Nephrotoxicity across
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nephrotoxicity across all treatment groups
Trial: 2108113
Drug: Aminoglycosides once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglycosides once daily
Trial: 30716477
Drug: Genetically estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for BE risk
Trial: 30716477
Drug: Genetically estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for EAC risk
Trial: 29227571
Drug: Metformin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin IR
Trial: 27741153
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment with Bifidobacterium breve BR03, B. breve B632, and Lactobacillus delbrueckii subsp. delbrueckii LDD01 at a concentration of 10 viable cells/strain/daily dose (5 drops)
Trial: 25172877
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin pump system in adolescent subgroup
Trial: 22965989
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus 81 mg of aspirin (n=28)
Trial: 22965989
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg only (n=28)
Trial: 20687826
Drug: Minocycline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline treatment for at least 2 weeks
Trial: 1974071
Drug: Alpidem 25-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem 25-150 mg daily
Trial: 1974071
Drug: Lorazepam 1-6
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1-6 mg daily
Trial: 7262175
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone injection at three different doses
Trial: 7262175
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone at five different doses